TY - JOUR
T1 - Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats
AU - Madeddu, P.
AU - Anania, V.
AU - Pinna Parpaglia, P.
AU - Demontis, M. P.
AU - Varoni, M. V.
AU - Pisanu, G.
AU - Troffa, C.
AU - Tonolo, G.
AU - Glorioso, N.
PY - 1992
Y1 - 1992
N2 - 1. The present study was designed to determine if endogenous kinins are involved in the regulation of arterial blood pressure and renal function in conscious rats given deoxycorticosterone enantate (DOC, 25 mg kg-1, s.c., weekly) or vehicle for two weeks. 2. The bradykinin B2-receptor antagonist, D-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe 140), at a dose of 300 μg kg-1, s.c., blocked the hypotensive effect of 300 ng kg-1 bradykinin i.a., but it did not alter the blood pressure lowering action of 300 ng kg-1 acetylcholine or prostaglandin E2. Inhibition of the response to bradykining persisted up to 6 h after the administration of Hoe 140. 3. Administration of 300 μg kg-1 Hoe 140 s.c. four times a day did not alter mean blood pressure, renal blood flow, or renal function in rats given DOC-vehicle. However, it decreased urinary volume by 70% (from 48.2 ± 3.8 to 14.3 ± 3.7 ml 24 h-1, P <0.01) and urinary secretion of sodium by 54% (from 1.02 ± 0.05 to 0.47 ± 0.16 mmol 24 h-1, P <0.01) and potassium by 30% (from 2.93 ± 0.15 to 2.04 ± 0.15 mmol 24 h-1, P <0.05) in DOC-treated rats. Mean blood pressure, glomerular filtration rate and total renal blood flow remained unchanged. 4. Our results suggest that endogenous kinins play a role in the regulation of renal excretion of water and sodium in the presence of elevated levels of DOC.
AB - 1. The present study was designed to determine if endogenous kinins are involved in the regulation of arterial blood pressure and renal function in conscious rats given deoxycorticosterone enantate (DOC, 25 mg kg-1, s.c., weekly) or vehicle for two weeks. 2. The bradykinin B2-receptor antagonist, D-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe 140), at a dose of 300 μg kg-1, s.c., blocked the hypotensive effect of 300 ng kg-1 bradykinin i.a., but it did not alter the blood pressure lowering action of 300 ng kg-1 acetylcholine or prostaglandin E2. Inhibition of the response to bradykining persisted up to 6 h after the administration of Hoe 140. 3. Administration of 300 μg kg-1 Hoe 140 s.c. four times a day did not alter mean blood pressure, renal blood flow, or renal function in rats given DOC-vehicle. However, it decreased urinary volume by 70% (from 48.2 ± 3.8 to 14.3 ± 3.7 ml 24 h-1, P <0.01) and urinary secretion of sodium by 54% (from 1.02 ± 0.05 to 0.47 ± 0.16 mmol 24 h-1, P <0.01) and potassium by 30% (from 2.93 ± 0.15 to 2.04 ± 0.15 mmol 24 h-1, P <0.05) in DOC-treated rats. Mean blood pressure, glomerular filtration rate and total renal blood flow remained unchanged. 4. Our results suggest that endogenous kinins play a role in the regulation of renal excretion of water and sodium in the presence of elevated levels of DOC.
KW - Blood pressure
KW - Bradykinin
KW - Hoe 140
KW - Kallikrein
KW - Kinin antagonist
KW - Renal blood flow
KW - Renal function
UR - http://www.scopus.com/inward/record.url?scp=0026519751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026519751&partnerID=8YFLogxK
M3 - Article
C2 - 1327379
AN - SCOPUS:0026519751
VL - 106
SP - 380
EP - 386
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 0007-1188
IS - 2
ER -